Last Price
14.98
Today's Change
0.00 (0.00%)
Day's Change
0.00 - 0.00
Trading Volume
0
Market Cap
750 Million
Shares Outstanding
50 Million
Avg Volume
82,914
Avg Price (50 Days)
14.66
Avg Price (200 Days)
15.09
PE Ratio
21.40
EPS
0.70
Earnings Announcement
20-Feb-2025
Previous Close
15.16
Open
15.20
Day's Range
14.81 - 15.2
Year Range
12.96 - 18.2
Trading Volume
65,380
1 Day Change
-1.19%
5 Day Change
-0.93%
1 Month Change
7.00%
3 Month Change
-0.27%
6 Month Change
7.46%
Ytd Change
-7.87%
1 Year Change
-7.30%
3 Year Change
-63.24%
5 Year Change
-41.55%
10 Year Change
229.23%
Max Change
389.54%
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. Clinuvel Pharmaceuticals Limited has a collaboration agreement with HK Winhealth Pharma Group Co. Limited t to treat EPP patients with SCENESSE under a named patient program in the People's Republic of China. The company was founded in 1987 and is headquartered in Melbourne, Australia.
Heavenly PUNTER Lynas Boleh
Potential 20 baggers
2019-06-11 14:49